In this interview from the ASRS 2014 Annual Meeting, Dr. Jeffrey Heier discusses phase 1 results with rAAV.sFlt-1, an adeno-associated virus carrying a soluble VEGF receptor. Injected into the subretinal space, rAAV.sFlt-1 is designed to transfect retinal cells to continuously inhibit VEGF. At 1 year, all 6 patients showed anatomic and visual improvement. Most impressive is the potential of anti-VEGF gene therapy to reduce the treatment burden for wet AMD patients. At 1 year, 4 of the 6 patients did not require retreatment with ranibizumab, while the 2 remaining required only one injection each.